Technical Analysis for PRTA - Prothena Corporation plc

Grade Last Price % Change Price Change
F 25.09 -3.76% -0.98
PRTA closed down 3.76 percent on Monday, March 18, 2024, on 80 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Signal Line Cross Bearish -3.76%
Narrow Range Bar Range Contraction -3.76%
Stochastic Reached Oversold Weakness -3.76%
BB Squeeze Ended Range Expansion -3.76%
Oversold Stochastic Weakness -3.76%
Fell Below 20 DMA Bearish -5.25%

   Recent Intraday Alerts

Alert Time
Down 5% about 16 hours ago
Down 3% about 17 hours ago
Fell Below Lower Bollinger Band about 17 hours ago
Fell Below Previous Day's Low about 17 hours ago
Down 2 % about 17 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Prothena Corporation plc Description

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biology Disease Antibodies Neuroscience Alzheimer's Disease Parkinson's Disease Neurological Disorders Dementia Psychiatric Diagnosis Amyotrophic Lateral Sclerosis Amyloid Neurodegeneration Aging Associated Diseases Lewy Body Dementia Treatment Of Alzheimer's Disease Histopathology Frontotemporal Dementia Alpha Synuclein

Is PRTA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 79.64
52 Week Low 24.285
Average Volume 864,808
200-Day Moving Average 46.27
50-Day Moving Average 29.91
20-Day Moving Average 27.99
10-Day Moving Average 27.91
Average True Range 1.70
RSI (14) 37.50
ADX 11.32
+DI 20.99
-DI 30.90
Chandelier Exit (Long, 3 ATRs) 25.92
Chandelier Exit (Short, 3 ATRs) 29.71
Upper Bollinger Bands 30.56
Lower Bollinger Band 25.41
Percent B (%b) -0.06
BandWidth 18.44
MACD Line -0.82
MACD Signal Line -0.63
MACD Histogram -0.1907
Fundamentals Value
Market Cap 1.35 Billion
Num Shares 53.7 Million
EPS -1.34
Price-to-Earnings (P/E) Ratio -18.72
Price-to-Sales 10.80
Price-to-Book 2.47
PEG Ratio 0.80
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.32
Resistance 3 (R3) 28.51 27.63 27.78
Resistance 2 (R2) 27.63 26.81 27.53 27.60
Resistance 1 (R1) 26.36 26.30 25.92 26.17 27.42
Pivot Point 25.48 25.48 25.26 25.38 25.48
Support 1 (S1) 24.21 24.66 23.77 24.02 22.76
Support 2 (S2) 23.33 24.15 23.23 22.58
Support 3 (S3) 22.06 23.33 22.40
Support 4 (S4) 21.87